Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Paul Bunn to Treatment Outcome

This is a "connection" page, showing publications Paul Bunn has written about Treatment Outcome.

 
Connection Strength
  
 
 
0.660
  
  1. Pacheco J, Bunn PA. Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133. Clin Lung Cancer. 2019 05; 20(3):148-160.e2.
    View in: PubMed
    Score: 0.061
  2. Hirsch FR, Dziadziuszko R, Varella-Garcia M, Franklin WA, Gandara DR, Bunn PA. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S138-42.
    View in: PubMed
    Score: 0.029
  3. Bunn PA. Diseases desperate grown. J Natl Cancer Inst. 2008 Apr 16; 100(8):520-1.
    View in: PubMed
    Score: 0.029
  4. Bunn PA, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. Oncologist. 2008; 13 Suppl 1:1-4.
    View in: PubMed
    Score: 0.029
  5. Bunn PA, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist. 2008; 13 Suppl 1:37-46.
    View in: PubMed
    Score: 0.029
  6. Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, Nguyen B, Paul S, McAndrews P, Hanna N, Kelly K, Bunn PA. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007 Mar; 18(3):453-60.
    View in: PubMed
    Score: 0.027
  7. Weiss GJ, Zeng C, Kelly K, Tran ZV, Bunn PA. Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. Clin Lung Cancer. 2007 Mar; 8(5):335-8.
    View in: PubMed
    Score: 0.027
  8. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2007 Apr; 18(4):752-60.
    View in: PubMed
    Score: 0.027
  9. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Bar?n A, Franklin WA, Hirsch FR, Geraci MW, Bunn PA. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res. 2006 Aug; 4(8):521-8.
    View in: PubMed
    Score: 0.026
  10. Bunn PA. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Clin Lung Cancer. 2004 Sep; 6(2):85-98.
    View in: PubMed
    Score: 0.023
  11. Bunn PA. Early-stage NSCLC: the role of radiotherapy and systemic therapy. J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 2:S31-40.
    View in: PubMed
    Score: 0.023
  12. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 01; 22(9):1589-97.
    View in: PubMed
    Score: 0.022
  13. Raben D, Helfrich B, Ciardiello F, Bunn PA. Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer. 2003 Aug; 41 Suppl 1:S15-22.
    View in: PubMed
    Score: 0.021
  14. Bunn PA, Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):341-3.
    View in: PubMed
    Score: 0.020
  15. Langston J, Patil T, Ross Camidge D, Bunn PA, Schenk EL, Pacheco JM, Jurica J, Waxweiler TV, Kavanagh BD, Rusthoven CG. CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer. Lung Cancer. 2023 04; 178:103-107.
    View in: PubMed
    Score: 0.020
  16. Simon GR, Bunn PA. Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. Cancer Invest. 2003; 21(1):87-104.
    View in: PubMed
    Score: 0.020
  17. Bunn PA, Chan DC, Earle K, Zhao TL, Helfrich B, Kelly K, Piazza G, Whitehead CM, Pamukcu R, Thompson W, Alila H. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):87-94.
    View in: PubMed
    Score: 0.019
  18. El Osta B, Behera M, Kim S, Berry LD, Sica G, Pillai RN, Owonikoko TK, Kris MG, Johnson BE, Kwiatkowski DJ, Sholl LM, Aisner DL, Bunn PA, Khuri FR, Ramalingam SS. Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2019 05; 14(5):876-889.
    View in: PubMed
    Score: 0.015
  19. Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, P?rol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018 08 01; 29(8):1701-1709.
    View in: PubMed
    Score: 0.015
  20. Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018 03 01; 24(5):1038-1047.
    View in: PubMed
    Score: 0.014
  21. Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 2017 02; 104:45-51.
    View in: PubMed
    Score: 0.013
  22. Bunn PA. The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 16):18-25.
    View in: PubMed
    Score: 0.013
  23. Bunn PA, Kelly KL. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol. 1995 Oct; 22(5 Suppl 12):54-8; discussion 59-60.
    View in: PubMed
    Score: 0.012
  24. Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014 Dec 01; 32(34):3824-30.
    View in: PubMed
    Score: 0.011
  25. Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, Franklin WA, Mao J, Wilson DO, Merrick DT, Hirsch FR, Kennedy TC, Bunn PA, Geraci MW, Miller YE. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila). 2011 Jun; 4(6):793-802.
    View in: PubMed
    Score: 0.009
  26. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol. 2010 May 01; 28(13):2174-80.
    View in: PubMed
    Score: 0.008
  27. Pisters KM, Valli?res E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010 Apr 10; 28(11):1843-9.
    View in: PubMed
    Score: 0.008
  28. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008 Jul 10; 26(20):3351-7.
    View in: PubMed
    Score: 0.007
  29. Weiss GJ, Vokes EE, Bunn PA, Magree L, Rusk J, Albert D, Kelly K. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8.
    View in: PubMed
    Score: 0.007
  30. Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA, Carbone DP. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007 Jun 06; 99(11):838-46.
    View in: PubMed
    Score: 0.007
  31. Dziadziuszko R, Holm B, Skov BG, Osterlind K, Sellers MV, Franklin WA, Bunn PA, Varella-Garcia M, Hirsch FR. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann Oncol. 2007 Mar; 18(3):447-52.
    View in: PubMed
    Score: 0.007
  32. Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006 Nov 01; 24(31):5034-42.
    View in: PubMed
    Score: 0.007
  33. Weiss GJ, Bunn PA, Camidge DR. From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer. Oncology (Williston Park). 2006 Nov; 20(12):1515-24; discussion 1524-5, 1530, 1535.
    View in: PubMed
    Score: 0.007
  34. Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, Nguyen B, Paul S, McAndrews P, Bunn PA, Kelly K. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Sep 20; 24(27):4405-11.
    View in: PubMed
    Score: 0.007
  35. Dziadziuszko R, Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV, Bar?n AE, Crino L, Franklin WA, Bunn PA, Varella-Garcia M, Danenberg KD, Hirsch FR. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res. 2006 May 15; 12(10):3078-84.
    View in: PubMed
    Score: 0.006
  36. Sunpaweravong P, Magree L, Rabinovitch R, Bunn P, Kelly K. A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. Invest New Drugs. 2006 May; 24(3):213-21.
    View in: PubMed
    Score: 0.006
  37. Thienelt CD, Bunn PA, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005 Dec 01; 23(34):8786-93.
    View in: PubMed
    Score: 0.006
  38. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA, Hirsch FR. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol. 2005 Aug 01; 23(22):5007-18.
    View in: PubMed
    Score: 0.006
  39. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA, Franklin WA, Crowley J, Gandara DR. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol. 2005 Oct 01; 23(28):6838-45.
    View in: PubMed
    Score: 0.006
  40. Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA, Chan DC, Pallansch P, Eckhardt SG. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2004 Nov 01; 10(21):7229-37.
    View in: PubMed
    Score: 0.006
  41. Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma. 2001 Mar; 41(1-2):77-87.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)